Key result
A new statistical method for comparing rates of rare adverse events with uncertain status in postmarketing safety studies was developed and demonstrated on a RotaTeq vaccine study.
A new statistical method was developed to compare rates of rare adverse events with uncertain status in postmarketing safety studies.
Offers a tool for postmarketing safety analyses of rare events; leaves open prospective validation before routine adoption.
We develop a simple statistic for comparing rates of rare adverse events between treatment groups in postmarketing safety studies where the events have uncertain status. In this setting, the statistic is asymptotically equivalent to the logrank statistic, but the limiting distribution has Poisson and binomial components instead of being Gaussian. We develop two new procedures for computing critical values: a Gaussian approximation and a parametric bootstrap. Both numerical and asymptotic properties of the procedures are studied. The test procedures are demonstrated on a postmarketing safety study of the RotaTeq vaccine. This vaccine was developed to reduce the incidence of severe diarrhea in infants.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2013) studied Rare adverse events with uncertain status. RotaTeq vaccine was evaluated on Rates of rare adverse events. A new statistical method for comparing rates of rare adverse events with uncertain status in postmarketing safety studies was developed and demonstrated on a RotaTeq vaccine study.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: